Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

We recently published Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks. In this article, we are going ...

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, ...

The U.S. office market in recent months and quarters has finally seen an uptick in leasing activity as companies became more ...

For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024. Product sales grew 11%, primarily driven by 14% ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

Lavina Talukdar; Senior Vice President & Head of Investor Relations; Moderna Inc. Stephane Bancel; Chief Executive Officer, Director; Moderna Inc. James Mock; Chief ...

Merck & Co. is caught in the middle of Wall Street's version of a group chat disagreement. Analysts gave it a “Moderate Buy” ...